PDCD1 and neoplasm: Both the anlotinib and anti‐PD‐1 monotherapy groups exhibited increased tumour necrosis relative to the control group, yet the most substantial necrosis was observed in the combined treatment group across both models (Figure 1F and Figure S2D, E; all p‐values < 0.001).